VJ/OA Oncology Journal Club (Breast Cancer): Prognostic implications of risk definitions from monarchE & NATALEE by Dr. Arecco
Study compared the prognostic impact of differing high-risk inclusion criteria used in the monarchE and NATALEE trials among patients with hormone receptor-positive/HER2-negative early #BreastCancer , using data from the MIG1, GIM2, and GIM3 trials. Patients were stratified into high- and low-risk cohorts per each trial’s criteria, and further grouped into concordant low-risk, discordant risk, and concordant high-risk categories.Link to Articlehttps://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaf031/8002826?login=false#google_vignette
--------
4:20
Oncology Here & Now (Lung Cancer): Dr. Marcelo Corassa & Dr. Biaggio Ricciuti discuss FLAURA, MARIPOSA & FLAURA2
Oncology here & nowIn this interview Dr. Biagio Ricciuti of Dana Farber Cancer Institute (USA) talks to Dr. Marcelo Corassa of beneficência Portuguesa de São Paulo (Brazil) as they discuss Treatments in EGFR mutant Non Small Cell Lung Cancer. The discussion centers around the results of FLAURA, MARIPOSA and FLAURA2, future directions and much more.Join Us
--------
20:11
The OncoAlert Weekly Round Up Covering April 4-10, 2025
Dear Colleagues,Welcome to the OncoAlert Weekly Round up Covering the TOP News and Trials THIS WEEK in Oncology. This week:Prognostic implications of risk definitions from the monarchE and NATALEE trialhttps://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaf031/8002826?login=false#google_vignetteEvaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancerhttps://link.springer.com/article/10.1007/s10549-025-07685-8?utm_content=buffer1d9c4&utm_medium=social&utm_source=twitter.com&utm_campaign=bufferFDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancerhttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancerCirculating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trialhttps://www.nature.com/articles/s41591-025-03579-wAssessment of a Polygenic Risk Score in Screening for Prostate Cancer (BARCODE1) https://nejm.org/doi/full/10.1056/NEJMoa2407934Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancerhttps://www.nature.com/articles/s41467-025-58435-9Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysishttps://www.annalsofoncology.org/article/S0923-7534(25)00130-9/abstract
--------
3:34
VJ/OA Oncology Journal Club: SANO Trial with Dr. van der Wilk (Oesophageal Cancer)
Dr. van der Wilk dives into the results of the SANO Trial in Oesophageal Cancer and recently published on the Lancet Oncology. The phase 3 trial investigated whether active surveillance could be a non-inferior alternative to standard surgery in individuals with oesophageal cancer who achieved a clinical complete response after neoadjuvant chemoradiotherapy. Conducted in 12 Dutch hospitals, the study randomized 309 participants to either active surveillance or standard oesophagectomy. After a median follow-up of 38 months, the 2-year overall survival for active surveillance (74%) was non-inferior to that of standard surgery (71%), with no significant differences in postoperative complications or mortality between groups. These results suggest active surveillance could be a viable option for patient counseling and shared decision-making, although extended follow-up is needed to assess long-term efficacy.
--------
6:30
VJ/OA Journal Club: LITESPARK 005 with Dr. Brian Rini & Dr. Tom Powles (KidneyCancer)
The phase 3 LITESPARK-005 trial evaluated patient-reported outcomes (PROs) for belzutifan, a HIF-2α inhibitor, versus everolimus in patients with advanced renal cell carcinoma previously treated with immune checkpoint and anti-angiogenic therapy.
Brasil